Research & Clinical Trials:

Dr. Ashwani Mehta, has left an indelible mark in the world of cardiology, spearheading 35 National & International clinical trials that have reshaped medical practices and guidelines."

•   SGRH. Dept of Cardiology is considered to be one of the best centre for Clinical research & trial in North India.

•   Received Achievement award for TMC CAN CHAMPION STUDY—Received GOLD MEDAL.

•   Epidemiological study done to look at incidence of Metabolic Syndrome in Indian Urban population.

•   Epidemological study undertaken to look at incidence of NIDDM and CAD Urban Population .

•   Study of risk factors of CAD in the young patients presenting with myocardial infarction .

•   Risk factor evalauation in females having MI as presentation at a young age .

List Of Latest, Completed & Ongoing Trials

•   Project Title : 110: A phase III randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF).

    Principal Investigator : Dr. Ashwani Mehta

    Investigational Drug / Indication : Empagliflozin

    No. of Patient Randomized / Screened : Screen – 45 | Randomized - 19

    Status : Completed

•   Project Title : 121: A phase III randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patient with chronic Heart Failure with reserved ejection fraction (HFrEF).

    Principal Investigator : Dr. Ashwani Mehta

    Investigational Drug / Indication : Empaglifozin

    No. of Patient Randomized / Screened : Screen – 78 | Randomized - 48

    Status : Completed

•   Project Title : Ultimaster: Prospective, single arm multicenter, observational Registry to further validate Safety and Efficacy of the ultimaster DES in Real world patient

    Principal Investigator : Dr. Ashwani Mehta

    Investigational Drug / Indication : Ultimaster Stent

    No. of Patient Randomized / Screened : 30

    Status : Completed

•   Project Title : A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, symptoms, exercise function and safety compared to individualized medical management of comorbidities in patients with heart failure and preserved ejection fraction

    Principal Investigator : Dr. Ashwani Mehta

    Investigational Drug / Indication : LCZ 696

    No. of Patient Randomized / Screened : Screen – 31 | Randomized - 13

    Status : Completed

•   Project Title : A multi-Center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to Ramipril on Morbidity and Mortality in High Risk Patient following an Acute Myocardial Infraction.

    Principal Investigator : Dr. Ashwani Mehta

    Investigational Drug / Indication : LCZ 696

    No. of Patient Randomized / Screened : Screen – 20 | Randomized – 20

    Status : Completed

•   Project Title : A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease

    Principal Investigator : Dr. Ashwani Mehta

    Investigational Drug / Indication : TQJ230

    No. of Patient Randomized / Screened : Screen – 66 | Randomized – 35

    Status : Ongoing

•   Project Title : A prospective, multicenter, randomized, open label, active controlled study to assess effect of Remogliflozin on biomarkers of heart failure compared to Empagliflozin in patients of type 2 diabetes mellitus with chronic heart failure (REMIT-HF)

    Principal Investigator : Dr. Ashwani Mehta

    Investigational Drug / Indication : Empagliflozin/ Remogliflozin

    No. of Patient Randomized / Screened : Screen – 08 | Randomized – 20

    Status : Completed

•   Project Title : Protocol number: (1245‐0202)‐ EMPACT‐MI: A streamlined, multicenter, randomized, parallel group, double blind placebo controlled,superiority trial to evaluate the effect of EMPAgliflozin on hospitalization for heart failure and mortality in patients with aCuTe myocardial infarction

    Principal Investigator : Dr. Ashwani Mehta

    Investigational Drug / Indication : Empagliflozin

    No. of Patient Randomized / Screened : Screen – 2 | Randomized – 2

    Status : Ongoing

Ongoing Major International Trials Aa Principal Investigator

• HORIZON STUDY – Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD
• EMPACT MI – EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
• LIB- TRIALS - Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction
• VICTORION-INITIATE - A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy